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Pancreatic disease can be notoriously difficult to diagnose so
there has been considerable interest recently in the develop-
ment of tests for serum glycoprotein markers of pancreatic
cancer. These have usually been carried out with the aid of
monoclonal antibodies produced against tumour or cell line
extracts. Potential serum markers for pancreatic cancer have
included carcinoembryonic antigen (CEA) (Gold & Freed-
man, 1965; Zamcheck & Martin, 1981), pancreatic oncofetal
antigen (POA) (Banwo et al., 1974; Nishida et al., 1985),
pancreatic carcinoma associated antigen (PCAA) (Schultz &
Yunis, 1979; Shimano et al., 1981), DU-PAN 2 (Metzgar et
al., 1984; Sawabu et al., 1986) and CA19-9 (Koprowski et al.,
1979; Magnani et al., 1983; Haglund et al., 1986). As most of
the marker antibodies so far characterised have been found
to recognise carbohydrate rather than protein epitopes (Feizi,
1985), a previous study was carried out to determine whether
further tumour marker glycoproteins could be more
efficiently identified using a combination of SDS-poly-
acrylamide gel electrophoresis and blotting with a panel of
lectins chosen for their ability to identify different carbohy-
drate epitopes. This approach proved successful demonstrat-
ing the presence of a high molecular weight glycoprotein in
approximately one-third (12/34) of the pancreatic cancer sera
but in none of the 96 controls (Ching & Rhodes, 1988).
Further characterisation showed this serum marker to be a
mucin (Ching & Rhodes, 1987a). This has subsequently been
developed into an enzyme-linked peanut lectin assay (PNA-
ELLA) (Ching & Rhodes, 1989) for total peanut lectin bind-
ing glycoproteins in serum. This assay has proved equivalent
in efficacy to CA19-9 serum radioimmunoassay and the two
tests together have a combined sensitivity of 85% for pan-
creatic cancer (Ching & Rhodes, 1989).
Although proving useful as a serum test for pancreatic
cancer, the epitope for CA19-9 is known to be present in
normal pancreatic tissue (Atkinson et al., 1982) and juice
(Kalthoff et al., 1986), bile (Albert et al., 1987) and colon
(Afdhal et al., 1987) in a way analogous to CEA (Go et al.,
1975; Huitric et al., 1976; Ichihara et al., 1988). This study
was performed to determine whether the peanut agglutinin
binding glycoprotein could also be detected in normal or
diseased pancreatic tissue.
Pancreatic resection specimens were obtained at
laparotomy from patients with pancreatic cancer (n = 3, all
well differentiated adenocarcinoma), normal (n = 5), chronic
pancreatitis (n = 4, all due to alcohol) and one ampullary
carcinoma. These were snap-frozen in liquid nitrogen and
then stored at - 70'C. Polyacrylamide gradient gels (2-16%)
were obtained from Pharmacia (Sweden), soybean trypsin
inhibitor and peroxidase-tagged peanut agglutinin (PNA, gal
1-3 gal NAc binding) from Sigma (USA), peroxidase-tagged
Ulex europaeus (UEA I, L-fucose binding), Limax flavus ag-
glutinin (LFA, sialic acid binding) and Griffonia simplicifolia
(GS 2, glc NAc binding) lectins from E-Y laboratory (USA)
and nitrocellulose paper from Bio-Rad (UK).
Pancreatic tissue glycoprotein extraction was performed
according to Rao and Shinozuka (1984) with minor
modification. Approximately I g wet weight pancreatic tissue
was used per specimen. Samples were cut into small pieces
and then ultrasonicated (Ultrasonicator KS 100, Kerry Ultra-
sonics, UK) for 1 min in 10 ml Tris HCI (20 mM, pH 7.4)/
EDTA (1 mM) buffer containing 200Lg ml-' soybean trypsin
inhibitor. This was followed by homogenisation in a Polytron
homogeniser (PCU, Kriens-Luzern, Switzerland) and then
centrifugation at 13,000g (Sorvall RC5, DuPont instruments,
USA) for 20 min. Supernatants were discarded because
preliminary analysis of concentrated supernatants from two
normal pancreatic tissues did not reveal any PNA binding
glycoproteins identifiable on lectin blotting from the gel. The
pellets were washed x 5 and then each sample re-
homogenised separately in I ml of the same buffer for 30 s.
One ml of the homogenised tissue was mixed with 9 ml of
chloroform/methanol (2: 1) mixture and stirred vigorously for
30 min. The aqueous phase was separated from the lipid
phase and the solid residue by centrifugation at 300 g (Cen-
taur 2, Fison instrumentation services, UK) for 20 min. The
aqueous phase was then concentrated by gentle evaporation
under nitrogen to approximately 1/4 of its original volume
and glycoprotein precipitation was carried out using nine
equivalent volumes of the aqueous phase of absolute ethanol.
The precipitate was obtained by centrifugation at 200 g for
10min.
Glycoprotein precipitates were reconstructed in 400 l of
de-ionised, distilled water. An aliquot was used for Lowry
protein estimation (Lowry et al., 1951). SDS-PAGE (using
approximately 100 iLg protein per sample), and then high
intensity transfer of proteins and glycoproteins on to nitro-
cellulose papers and finally identification of PNA binding
glycoproteins on the blots were performed as described
before (Ching & Rhodes, 1988). The high molecular weight
PNA binding glycoprotein identified in the tissue extracts
was then further characterised using other lectins, UEA I
(25jgml-'), LFA (12.5 ig ml-') and GS 2 (25 JLgml-').
The mean yield of water soluble protein obtained from one
extraction step ranged between 2-4.5 mg g-' pancreatic tis-
sue. A high molecular weight (approximately 3.5 million Da)
PNA binding glycoprotein (lane 3, Figure 1) having identical
electrophoretic mobility to the serum marker, both before
and after purification, was identified in tissue extracts from
3/3 pancreatic cancers, 1/4 chronic pancreatitis and 2/5 nor-
mals. The sole ampullary carcinoma extract studied did not
contain the high molecular weight glycoprotein at
3.5 x 106 Da but it showed a strong PNA binding region
around 1 x 106 Da, indicating the possibility of another
tumour related PNA + glycoprotein in this epithelial car-
cinoma. A lower molecular weight (50,000 Da approximately)
peanut agglutinin binding glycoprotein was also present. This
was co-purified with the 3.5 million Da glycoprotein and was
still present after the 3.5 million Da glycoprotein had been
cut out of the gel, eluted and rerun. Characterisation of the
water soluble pancreatic tissue PNA binding 3.5 million Da
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Figure 1 Result of peroxidase-PNA lectin blotting after electro-
phoresis on a 2-16% SDS-polyacrylamide gel showing the
presence of the high molecular weight glycoprotein (arrowed) in
pancreatic cancer (lane 3) and normal pancreatic (lane 5) tissue
extracts having the same electrophoretic mobility as the serum
marker. Lane 1, purified serum marker from pancreatic cancer;
lane 2, original pancreatic cancer serum of sample loaded in lane
I; lane 4, ampullary carcinoma tissue extract. Molecular weight
markers: Thy, thyroglobulin 330,000 Da; Ferl, ferritin 1
220,000 Da; Alb, albumin 67,000 Da; Cat, catalase 60,000 Da;
Lac, lactate dehydrogenase 36,000 Da Fer2 ferritin 2 18,500 Da.
glycoprotein by the use of other lectins showed that it bound
LFA but not UEA I and GS 2 lectins (Table I) indicating the
expression of the epitopes gal 1-3 gal NAc (blood group T
antigen), and sialic acid but not L-fucose (blood group H
antigen) or GIc NAc (blood group Tk antigen). Other PNA
binding glycoproteins present on the blots are probably nor-
mal pancreatic epithelial structure components as we have
previously shown in a lectin histochemical study that PNA
binding glycoproteins other than the secreted mucus can be
identified (Ching et al., 1988).
This study has demonstrated that a peanut lectin (PNA)
binding glycoprotein previously found in pancreatic cancer
serum is also present in the pancreatic tissue itself not only in
pancreatic cancer but also in benign pancreatic disease and in
the normal pancreas. Both serum and tissue PNA binding
glycoproteins had identical electrophoretic mobility. The lec-
tin binding characteristics of the tissue glycoprotein extracted
from benign and malignant pancreas indicate that it pos-
sesses gal I1-3 gal NAc (PNA binding) and sialic acid (LFA
binding) side chains. These epitopes have been demonstrated
on the serum glycoprotein (Table I) which variably bears
additional epitopes namely L-fuCose (H antigen, UEA I bind-
ing) and glc NAc (Tk antigen, GS2 binding) (Ching &
Rhodes, 1987b).
The demonstration of the high molecular weight PNA
binding glycoprotein in pancreatic tissue makes it very likely
(Ching~~"5 &'Rhodes', 1988 in paceai cace sera 9is indeed::
coming~~~....... fromC the pacra. Shddn of muci ino seu
appears to besamoereuarfatr of parxds-N etnbotncreaftic canero
Table I Lectin binding characteristics of the high molecular weight
pancreatic cancer-related serum and water soluble tissue
glycoproteins





(+), variable binding of the high mol. wt serum glycoprotein to
the lectins (7/12 to UEA I and 4/12 to both LFA and GS 2) (Ching
& Rhodes, 1987b).
compared with gastrointestinal tumours such as colonic and
gastric tumours as shown by the higher rate ofpositive serum
tests in pancreatic cancer using both enzyme-linked PNA
assay and CA19-9 radioimmunoassay, even though the
CA19-9 antibody was raised against a colorectal cancer cell
line. In a previous study, we have shown that the PNA
binding pancreatic cancer-related serum mucus glycoprotein
sometimes but not always expresses the CA19-9 epitope
(Ching & Rhodes, 1988). The binding sites for PNA (gal 1-3
gal NAc) and CA19-9 (sialylated N-fucopentaose II oligosac-
charide) cannot occur on the same oligosaccharide side
chains so we envisage the tumour-related mucin as a complex
glycoprotein that may variably express the sialylated Lewis
antigen (CA19-9 epitope) on some side chains, the PNA
epitope (T antigen) on others and UEA I (H antigen) and
GS2 (Tk antigen) binding sites on yet other side chains.
Simultaneous demonstration of an additional carbohydrate
epitope (CA-242) on the tumour marker glycoprotein CA5O
has also been reported recently (Nilsson et al., 1988).
The sialylated Lewisa antigen has been found in normal
colon (Afdhal et al., 1987), bile (Albert et al., 1987) and
pancreatic juice (Kalthoff et al., 1986) so seems to be a
normal tissue and mucin glycoprotein that is abnormally
expressed in the serum in cancer rather than an oncofetal
antigen. The status of the PNA binding site (T antigen) is
more uncertain. It behaves more as an oncofetal antigen in
colon (Boland et al., 1982; Cooper, 1984; Rhodes et al.,
1986), breast (Howard et al., 1981), stomach (Kuhlmann et
al., 1983), ovary (Soderstrom, 1988) and lymphoid (Ree &
Hsu, 1983) tissue. It can be predicted from the known struc-
ture of mucin that the T antigen can only be present as the
base pair of the oligosaccharide side chain (Hounsell & Feizi,
1982) which is usually concealed by further glycosylation or
sialylation. It seems likely that its expression at least reflects
a relatively immature mucin side chain. In a previous study
using lectin histochemistry, PNA binding has however been
found variably in normal pancreatic cytoplasm (Ching et al.,
1988) and in normal large bile ducts (Rhodes et al., 1988)
and the study presented here confirms that it can be variably
expressed in normal pancreas.
The presence of mucin in serum is perhaps surprising, but
the CA19-9 epitope bearing mucin has also been found in
pancreatic cancer (Haglund et al., 1986) and in patients with
cystic fibrosis (Roberts et al., 1986). In pancreatic cancer, this
might reflect either early invasion of this tumour into blood
vessels or early ductal obstruction with reflux. It is clear from
our study that this mucin contains at least four different
oligosaccharide side chain structures and probably many
more so development of a panel of monoclonal antibodies
against different epitopes on this mucin may lead to the
development of a more sensitive and specific test for pan-
creatic cancer.
C.K.C. was an Amelie Waring research fellow of the British Diges-
tive Foundation.
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